Romlusevimab (BRII-198) is a recombinant antibody targeting the spike protein of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), with antiviral activity, used for research on COVID-19 infection.
Purity:
100.00%
CAS Number:
[2509447-08-7]
Target:
SARS-CoV
* VAT and and shipping costs not included. Errors and price changes excepted